BOSTON, November 17, 2025 — Leads & Copy — The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Dewpoint Therapeutics’ DPTX3186, an oral condensate modulator targeting the Wnt/β-catenin pathway, for the treatment of gastric cancer.
The Fast Track designation aims to accelerate the development and review of therapies for serious conditions with unmet medical needs. It provides Dewpoint Therapeutics with increased access to the FDA through more frequent communication, eligibility for rolling review of future New Drug Application (NDA) components, and the potential for accelerated timelines.
Isaac Klein, MD PhD, Chief Scientific Officer and Head of R&D at Dewpoint Therapeutics, expressed honor at the FDA’s recognition of the urgency of gastric cancer and the potential of their condensate-based approach. Klein stated that DPTX3186 represents a new way of modulating disease-relevant biology and could offer a meaningful option for patients with limited treatments. He also noted that the Fast Track designation provides an important framework to advance the program with greater efficiency and speed.
DPTX3186 is a first-in-class small molecule designed to modulate the oncogenic function of β-catenin, a central driver of gastric cancer and several other solid tumors. The therapy aims to reduce aberrant β-catenin signaling while preserving normal cellular function by sequestering β-catenin in a drug-induced condensate.
The FDA recently opened the company’s IND for DPTX3186 and granted the program an Orphan Drug Designation. Dewpoint Therapeutics is now initiating a Phase 1a/2a clinical trial across leading cancer centers in the United States.
Ameet Nathwani, MD, Chief Executive Officer of Dewpoint Therapeutics, said that the Fast Track designation recognizes the promise of their condensate modulators to address serious diseases through a new biological lens. He added that it provides an important regulatory framework that can help them advance DPTX3186 more efficiently, maximizing the speed and impact with which they can deliver novel therapies to patients in diseases with high unmet need.
Gastric cancer remains a leading cause of cancer mortality worldwide. Dewpoint Therapeutics expects to dose the first patient in the DPTX3186 clinical trial before the end of the year.
Dewpoint is a clinical-stage biotech company focused on applying biomolecular condensate biology to develop a new generation of therapeutics for diseases with high unmet need. Their proprietary AI/ML-powered integrated platform supports a drug discovery pipeline spanning multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. They have collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma Corporation.
Condensates are membraneless organelles that form dynamically throughout the cell via phase separation, organizing and concentrating molecules within cells to enable key biochemical processes. Dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary, and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets.
Media Contact: media@dewpointx.com
Investor Contact: IR@dewpointx.com
Source: Dewpoint Therapeutics
